Page 2 of 3
123

2020 (3 POSTS)

Chappell GA, Thompson CM, Wolf JC, Cullen JM, Klaunig JE, Haws LC. 2020. Assessment of the mode of action underlying the effects of GenX in mouse liver and implications for assessing human health risks. Toxicol Pathol 48(3):494–508; doi: 10.1177/0192623320905803. PMID: 32138627.

View Abstract

Haws L (session co-chair). Introduction to “Use of New Approach Methods in Risk Characterization of PFAS: Challenges and Opportunities.” 44th Annual Winter Meeting, the Toxicology Forum, Tysons, VA, January 2020.

Thompson CM, Ring C, Pham L, Chappell GA, Haws LC. Assessment of the relevance of toxicological findings in the development of an oral reference dose for GenX. Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.

View Abstract

2019 (6 POSTS)

Thompson C, Chappell G, Cullen J, Wolf JC, Haws L. Development of an oral reference dose for GenX using the latest toxicological and risk assessment methodologies: Environmental risk assessment of per- and polyfluoroalkyl substances (PFAS). SETAC North America Focused Topic Meeting, Durham, NC, August 2019.

Chappell GA, Thompson CM, Wolf J, Cullen J, Haws LC. Transcriptomic responses in livers of GenX-treated mice demonstrate up-regulation of PPAR signaling and related pathways. Environmental Mutagenesis and Genomics Society, Washington, DC, September 2019.

Thompson CM. The useful chemistry of perfluorinated compounds: Managing safety. The sticky subject of non-stick: Regulatory science challenges of per- and poly-fluorinated compounds (PFAS). Texas A&M University Interdisciplinary Faculty of Toxicology Training Program, 2019 Annual Regulatory Science Symposium, August 2019.

Thompson CM, Fitch SE, Ring C, Rish W, Cullen JM, Haws LC. 2019. Development of an oral reference dose for the perfluorinated compound GenX. J Appl Toxicol 39(9):1267–1282; doi: 10.1002/jat.3812.

View Abstract

Ring CL, Rish WR, Brorby GL. Prioritization of eight PFAS by population exposure and reference-dose uncertainty. Poster session at SETAC North America Focused Topic Meeting “Environmental Risk Assessment of PFAS”, Durham, NC, August 2019.

Borghoff SJ, Fitch S, Huggett, Wikoff D. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine disrupting properties of perfluorohexanoic acid (PFHxA). 2019. Poster at Society of Toxicology Annual Meeting, Baltimore, MD, March 2019.

View Abstract

2018 (2 POSTS)

Borghoff SJ, Fitch S, Rager JE, Huggett D. 2018. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine activity of perfluorohexanoic acid. Regul Toxicol Pharmacol 99(Nov):168–181; doi: 10.1016/j.yrtph.2018.09.001.

View Abstract

Kempisty DM, Xing Y, Racz L (eds). 2018. Perfluoroalkyl Substances in the Environment: Theory, Practice and Innovation. Taylor and Francis CRC Press: Boca Raton, FL.

View Abstract

2007 (1 POST)

Paustenbach DJ, Panko JM, Scott PK, Unice KM. 2007. A methodology for estimating human exposure to perfluorooctanoic acid (PFOA): A retrospective exposure assessment of a community (1951-2003). J Toxicol Environ Health A 70(1):28–57; doi: 10.1080/15287390600748815.

View Abstract

2006 (2 POSTS)

Paustenbach DJ, Panko JM, Scott PK, Unice KM. Retrospective modeling of potential residential exposure to perfluorooctanoic acid (PFOA) releases from a manufacturing facility. Society of Toxicology 45th Annual Meeting, San Diego, CA, March 2006.

Lau C, Thibodeaux JR, Hanson RG, Narotsky MG, Rogers JM, Lindstrom AB, Strynar MJ. 2006. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol Sci 90(2):510–518; doi: 10.1093/toxsci/kfj105.

View Abstract

2005 (2 POSTS)

Grasty RC, Bjork JA, Wallace KB, Lau CS, Rogers JM. 2005. Effects of prenatal perfluorooctane sulfonate (PFOS) exposure on lung maturation in the perinatal rat. Birth Defects Res B 74(5):405–416; doi: 10.1002/bdrb.20059.

View Abstract

Grasty RC, Roberts N, Klinefelter G, Bjork JA, Wallace KB, Lau CS, Rogers JM. 2005. Effects of prenatal perfluorooctanesulfonate (PFOS) exposure on lung maturation in the perinatal rat. Birth Defects Res A 73:314.

2004 (3 POSTS)

Lau C, JL Butenhoff, JM Rogers. 2004. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol 198(2):231-241; doi: 10.1016/j.taap.2003.11.031.

View Abstract

Grasty RC, Roberts N, Grey BE, Lau C, Rogers JM. Effects of prenatal exposure to perfluorooctane sulfonate on the developing lung in the rat. Society for Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.

Grasty RC, Roberts N, Grey BE, Lau C, Rogers JM. 2004. Perfluorooctane sulfonate (PFOS) alters lung development in the neonatal rat. Birth Defects Res A 70(5):42.

2003 (4 POSTS)

Grasty RC, Grey BE, Lau CS, Rogers JM. 2003. Window of susceptibility to perfluorooctane sulfonate (PFOS)-induced neonatal mortality in the rat. Birth Defects Research B 68(3):5.

Page 2 of 3
123